Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomaviruse types 16 and 18

Vaccine

Volumn 32, Issue 44, 2014, Pages 5880-5887

  Brown, Darron ^a   Müller, Martin ^b   Sehr, Peter ^c   Pawlita, Michael ^b   Seitz, Hanna ^b,e   Rubio, Ivonne ^b,f   Antonello, Joseph ^d   Radley, David ^d,g   Roberts, Christine ^d   Saah, Alfred ^d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^d MERCK RESEARCH LABORATORIES   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f Pfizer Inc ^*  (United Kingdom)

^g PFIZER INC   (United States)

Author keywords

Antibodies; HPV; Vaccine

Indexed keywords

IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; WART VIRUS VACCINE;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOASSAY; LIMIT OF QUANTITATION; NONHUMAN; PAPILLOMAVIRUS INFECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PSEUDOVIRION BASED NEUTRALIZATION ASSAY; VACCINATION; VIRUS DETECTION; VIRUS NEUTRALIZATION; BLOOD; COMPARATIVE STUDY; FEMALE; ISOLATION AND PURIFICATION; MALE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SERODIAGNOSIS; STATISTICAL MODEL; TIME;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN G; LINEAR MODELS; MALE; NEUTRALIZATION TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 84908065072     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.08.004     Document Type: Article

References (16)

1. International Agency for Research on Cancer 2013 IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Vol 100, A Review of Human Carcinogens. Part B: Biological Agents 2011, International Agency for Research on Cancer, Lyon, France.
2. Orozco J.J., Carter J.J., Koutsky L.A., Galloway D.A. Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 l1 capsomers. J Virol 2005, 79:9503-9514.
3. Christensen N.D., Dillner J., Eklund C., Carter J.J., Wipf G.C., Reed C.A., et al. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 1996, 223:174-184.
4. Carter J.J., Wipf G.C., Madeleine M.M., Schwartz S.M., Koutsky L.A., Galloway D.A. Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera. J Virol 2006, 80:4664-4672.
5. Dias D., Van Doren J., Schlottmann S., Kelly S., Puchalski D., Ruiz W., et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomavirus 6, 11, 16 and 18. Clin Diagn Lab Immunol 2005, 12:959-969.
6. Opalka D., Lachman C.E., MacMullen S.A., Jansen K.U., Smith J.F., Chirmule N., et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16 and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 2003, 10:108-115.
7. Joura E.A., Kjaer S.K., Wheeler C.M., Sigurdsson K., Iversen O.E., Hernandez-Avila M., et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 2008, 26:6844-6851.
8. Opalka D., Matys K., Bojczuk P., Green T., Gesser R., Saah A., et al. Multiplexed serologic assay for nine anogenital human papillomavirus types. Clin Vaccine Immunol 2010, 17:818-827.
9. Brown D.R., Garland S.M., Ferris D.G., Joura E., Steben M., James M., et al. The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay. Hum Vaccin 2011, 7:230-238.
10. Pastrana D.V., Buck C.B., Pang Y.Y., Thompson C.D., Castle P.E., FitzGerald P.C., et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 2004, 321:205-216.
11. Sehr P., Rubio I., Seitz H., Putzker K., Ribeiro-Muller L., Pawlita M., et al. High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses. PLoS One 2013, 8:e75677.
12. Wheeler C.M., Bautista O.M., Tomassini J.E., Nelson M., Sattler C.A., Barr E. Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine 2008, 26:686-696.
13. Munoz N., Manalastas R., Pitisuttihum P., Tresukosol D., Monsonego J., Ault K., et al. Safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women between 24 and 45 years of age: a randomized, double-blind trial. Lancet 2009, 373:1949-1957.
14. Giuliano A.R., Palefsky J.M., Goldstone S., Moreira E.D., Penny M.E., Aranda C., et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 2011, 364:401-411.
15. Tan C.Y., Iglewicz B. Measurement-methods comparisons and linear statistical relationship. Technometrics Vol. 41 1999, No. 3.
16. Roberts C., Green T., Hess E., et al. Development of a human papillomavirus competitive luminex immunoassay for nine HPV types. Hum Vaccin Immunother 2014, 10. [Epub ahead of print], Pubmed ID 24955587.